Ultrasound-Guided Three-Level Intercostal Blockade for Tietze Syndrome: Retrospective Analgesic Outcomes
International Trakya Family Medicine Congress, Edirne, Türkiye, 16 - 19 Nisan 2026, ss.98-99, (Özet Bildiri)
- Yayın Türü: Bildiri / Özet Bildiri
- Basıldığı Şehir: Edirne
- Basıldığı Ülke: Türkiye
- Sayfa Sayıları: ss.98-99
- İstanbul Üniversitesi Adresli: Hayır
Özet
Aim:
Tietze syndrome can impose a clinically meaningful burden
through persistent anterior chest wall pain, tenderness, and
activity limitation, thereby impairing daily functioning and quality
of life. Interventional management of refractory Tietze syndrome
in the literature has largely focused on local costochondral
injections, most commonly combining corticosteroid with local
anesthetic, while ultrasound guidance is increasingly used to
enhance targeting and procedural safety. We aim to evaluated
the mid-term analgesic impact and safety of ultrasound-guided
(USG) three-level intercostal nerve blockade performed as a
targeted regional analgesic strategy.
Method:
We conducted a retrospective, single-center cohort study of
patients treated for clinically diagnosed Tietze syndrome with
USG-guided intercostal blockade. The block was standardized
to the maximally painful intercostal level and the adjacent cranial
and caudal levels (painful level ±1). Under real-time ultrasound
guidance, a bupivacaine–lidocaine local anesthetic mixture was
injected at 3 mL per level (total 9 mL). Pain intensity was
quantified using the visual analog scale (VAS) immediately
before intervention and at the 3rd-month follow-up. Continuous
variables are reported as mean±SD.
Results:
Twenty-three patients were included. Mean pre-procedural VAS
was 7.87±1.42 and decreased to 2.52±2.69 at 3 months,
yielding an absolute mean reduction of 5.35 VAS units. No
procedure-related
complications
or
adverse
events
were
recorded.
Conclusions:
In this retrospective series, USG-guided three-level intercostal
blockade using a bupivacaine–lidocaine mixture was associated
with substantial pain reduction sustained to 3 months and an
excellent safety profile. These data support the feasibility of a
focused ultrasound-guided regional approach for symptomatic
Tietze
syndrome;
prospective
controlled
studies
with
standardized diagnostic criteria and functional endpoints are
needed to define comparative effectiveness and durability